Abstract
One of the best approaches against cancer is prevention. Inactivation of the p53 or p16INK4a genes has been extensively reported in most human cancer cells. Both p53 and p16INK4a function as tumor suppressors. Therefore, functional restoration of these molecules is considered to be one of the most useful methods for cancer prevention and therapy. We have proposed a concept termed ‘gene-regulating chemoprevention and chemotherapy’ regarding the above pathway. This concept assumes that transcriptional regulation by drugs on tumor-suppressor genes, downstream target genes or functionally similar genes (for example, family genes) of the tumor-suppressor genes would contribute to the prevention of human malignancies. Histone deacetylase (HDAC) inhibitors have been shown to be potent inducers of growth arrest, differentiation and apoptotic cell death. Previously, we demonstrated that HDAC inhibitors, such as sodium butyrate and trichostatin A (TSA), transcriptionally induce the cyclin-dependent kinase inhibitor p21WAF1/Cip1, a downstream target gene of p53, in a p53-independent manner. Furthermore, we have recently shown that HDAC inhibitors activate Gadd45, another downstream target gene of p53, and p19INK4d, a gene functionally similar to p16INK4a. Our results, taken together with previous findings, suggest that HDAC inhibitors may be one of the most attractive and promising agents for ‘gene-regulating chemoprevention’ and ‘molecular-targeting prevention’ of cancer.
Key words: histone deacetylase inhibitors, prevention, p53, p16INK4a, p21WAF1/Cip1, Gadd45, p19INK4d
References
- (1).Pitot HC. The molecular biology of carcinogenesis. Cancer 1993; 72: 962–970. [DOI] [PubMed]
- (2).Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nature Rev. Cancer 2002; 2: 537–543. [DOI] [PubMed]
- (3).Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ. 2001; 12: 337–349. [PubMed]
- (4).Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999; 18: 5311–5317. [DOI] [PubMed]
- (5).Varley JM, Evans DGR, Birch JM. Li-Fraumeni syndrome—a molecular and clinical review. Br. J. Cancer 1997; 76: 1–14. [DOI] [PMC free article] [PubMed]
- (6).Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996; 10: 1054–1072. [DOI] [PubMed]
- (7).Smith-Sorenson B, Hovig E. CDKN2A (p16INK4A) somatic and germline mutations. Hum. Mutat. 1996; 7: 294–303. [DOI] [PubMed]
- (8).Sakai T. Molecular cancer epidemiology—the present status and future possibilities. Jpn. J. Hyg. 1996; 50: 1036–1046. [DOI] [PubMed]
- (9).Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene 1995; 11: 1211–1216. [PubMed]
- (10).Sowa Y, Sakai T. Butyrate as a model for “Gene-regulating chemoprevention and chemotherapy. Biofactors 2000; 12: 283–287. [DOI] [PubMed]
- (11).Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000; 92: 1210–1216. [DOI] [PubMed]
- (12).Scheppach W, Bartram HP, Richter F. Role of short-chain fatty acids in the prevention of colorectal cancer. Eur. J. Cancer 1995; 31A: 1077–1080. [DOI] [PubMed]
- (13).McIntyre A, Gibson PR, Young GP. Butyrate production from dietary fiber and protection against large bowel cancer in a rat model. Gut 1993; 34: 386–391. [DOI] [PMC free article] [PubMed]
- (14).Weber GA, Krause JA, Miller TL, Wolin MJ. Short chain fatty acid distribution of enema samples from a sigmoidoscopy population: an association of high acetate and low butyrate ratios with adenomatous polyps and colon cancer. Gut 1988; 29: 1539–1543. [DOI] [PMC free article] [PubMed]
- (15).Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B, Speizer FE, Willett WC. Dietary fiber and the risk of colorectal cancer and adenoma in women. N. Engl. J. Med. 1999; 340: 169–176. [DOI] [PubMed]
- (16).Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J. Biol. Chem. 1997; 272: 22199–22206. [DOI] [PubMed]
- (17).Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13: 1501–1512. [DOI] [PubMed]
- (18).Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T. Histone deacetylase inhibitor activates the WaF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 1997; 241: 142–150. [DOI] [PubMed]
- (19).Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000; 19: 5712–5719. [DOI] [PubMed]
- (20).Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. 1999; 19: 4999–5005. [PubMed]
- (21).Suske G. The Sp-family transcription factors. Gene 1999; 238: 291–300. [DOI] [PubMed]
- (22).Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res. 1999; 59: 4266–4270. [PubMed]
- (23).Hirose T, Sowa Y, Takahashi S, Saito S, Yasuda C, Shindo N, Sakai T. p53-independent induction of Gadd45 by histone deacetylase inhibitor: Coordinate regulation by transcriptional factors Oct-1 and NF-Y. Oncogene in press. [DOI] [PubMed]
- (24).Yokota T, Matsuzaki Y, Sakai T. Histone deacetylase inhibitors activate p19INK4d gene through Sp1 site in its promoter. Proc. Am. Assoc. Cancer Res. 2003; 44: 1008. [DOI] [PubMed]
- (25).Sheikh MS, Hollander MC, Fornace AJ Jr. Role of Gadd45 in apoptosis. Biochem. Pharmacol. 2000; 59: 43–45. [DOI] [PubMed]
- (26).Sowa Y, Sakai T. Gene-regulating chemoprevention against cancer-As a model for “Molecular-targeting prevention” of cancer. Jpn. J. Hyg. 2003; 58: 267–274. [DOI] [PubMed]
- (27).Tominaga S. Major avoidable risk factors of cancer. Cancer Lett. 1999; 143: 19–23. [DOI] [PubMed]